This is a routine pipeline update with no new financial data. The F351 NDA acceptance in China is a positive regulatory milestone but was previously disclosed. Monitor for NMPA approval decision on F351 and initiation of US Phase 2 for MASH in 2027. The CG001419 safety data is early but encouraging for the pain program.
Price Chart
Executive Summary
Gyre Therapeutics filed an 8-K furnishing an updated corporate investor presentation. The presentation highlights the company's pipeline following the Cullgen acquisition, including positive Phase 3 data for F351 (hydronidone) in CHB-associated liver fibrosis (52.85% fibrosis regression vs 29.84% placebo, p=0.0002) with NDA accepted by China's NMPA in May 2026, and early-stage clinical data for CG001419 (TRK degrader) showing no DLTs in 22 patients. No new financial guidance or material financial data was provided.
Key Facts
- F351 Phase 3 trial met primary endpoint: 52.85% 1-stage fibrosis regression at Week 52 vs 29.84% placebo (p=0.0002)
- F351 NDA accepted by China NMPA in May 2026 with Breakthrough Therapy Designation and Priority Review
- CG001419 Phase 1a data from first 22 patients showed no DLTs, treatment-related SAEs, or Grade 3 treatment-related AEs
- CG009301 Phase 1 dose escalation underway; first 8 patients showed no DLTs
- CDK2-Cyclin E degrader (CG923308) IND anticipated Q1 2027
- Company has ~740 employees worldwide with operations in San Diego, Shanghai, and Beijing
- No financial results, guidance, or material financial data were disclosed in this filing
Financial Impact
No financial figures disclosed; filing is a routine corporate presentation update
Risk Factors
- F351 approval and commercialization in China subject to regulatory and competitive risks
- All pipeline candidates are in early to mid-stage development with no guarantee of clinical or regulatory success
- Reliance on China operations introduces geopolitical and operational risks
- No new financial data to assess cash runway or revenue trajectory
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-023625 |
| Document: ef20075381_8k.htm | 0001140361-26-023625 |
| Document: 0001140361-26-023625-index-headers.html | 0001140361-26-023625 |
| Document: 0001140361-26-023625-index.html | 0001140361-26-023625 |
| Document: 0001140361-26-023625.txt | 0001140361-26-023625 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $5.85 | awaiting T+20 | — | $6.37 (+8.91%) |
Sep 1, 2026 8w ago | 8-K | $6.47 $7.35 | ▲ +13.52% | ▲ +12.34% | $6.37 (−1.52%) |
Aug 26, 2026 8w ago | 8-K | $6.65 $7.43 | ▲ +11.73% | ▲ +10.53% | $6.37 (−4.19%) |
Aug 7, 2026 11w ago | 8-K | $6.67 $6.86 | ▼ −2.85% | ▼ −3.25% | $6.37 (+4.48%) |
Aug 4, 2026 12w ago | EFFECT | $6.15 $6.47 | ▲ +5.20% | ▲ +6.44% | $6.37 (+3.60%) |
Jul 13, 2026 15w ago | S-3/A | $6.34 $6.64 | ▲ +4.73% | ▲ +2.24% | $6.37 (+0.50%) |
Jun 2, 2026 21w ago | 8-K | $5.56 $6.52 | ▲ +17.27% | ▲ +18.83% | $6.37 (+14.60%) |
May 14, 2026 23w ago | 8-K | $6.55 $5.86 | ▼ −10.53% | ▼ −12.65% | $6.37 (−2.73%) |
May 4, 2026 25w ago | 8-K / DEFA14A | $7.92 $5.81 | ▼ −26.64% | ▼ −32.29% | $6.37 (−19.55%) |
May 4, 2026 25w ago | Press Release | $7.92 $5.81 | ▼ −26.64% | ▼ −32.29% | $6.37 (−19.55%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers